down arrow

Zhejiang Xianju Pharmaceutical Co., Ltd.

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE100000K64
  • SHE: 002332
CNY
8.74
0.08 (0.92%)

Sep 22

SHE

 View all stocks in this country
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Zhejiang Xianju Pharmaceutical Co., Ltd.

Why is Zhejiang Xianju Pharmaceutical Co., Ltd. ?

1
Poor long term growth as Net Sales has grown by an annual rate of -2.93% and Operating profit at -12.37% over the last 5 years
2
The company has declared Negative results for the last 6 consecutive quarters
  • INTEREST(HY) At CNY 2.15 MM has Grown at 13.33%
  • INVENTORY TURNOVER RATIO(HY) Lowest at 1.4 times
  • DEBTORS TURNOVER RATIO(HY) Lowest at 3.4 times
3
Consistent Underperformance against the benchmark over the last 3 years
  • Along with generating -10.47% returns in the last 1 year, the stock has also underperformed China Shanghai Composite in each of the last 3 annual periods
stock-recommendationReal-Time Research Report

Verdict Report

How much should you buy?

  1. Overall Portfolio exposure to Zhejiang Xianju Pharmaceutical Co., Ltd. should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Zhejiang Xianju Pharmaceutical Co., Ltd. for you?

Low Risk, Low Return

Absolute
Risk Adjusted
Volatility
Zhejiang Xianju Pharmaceutical Co., Ltd.
-11.63%
-1.23
23.04%
China Shanghai Composite
3.23%
1.20
14.07%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
-2.93%
EBIT Growth (5y)
-12.37%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.21
Sales to Capital Employed (avg)
0.63
Tax Ratio
15.88%
Dividend Payout Ratio
65.99%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
13.00%
ROE (avg)
11.04%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
20
Industry P/E
Price to Book Value
1.31
EV to EBIT
18.97
EV to EBITDA
13.17
EV to Capital Employed
1.38
EV to Sales
1.89
PEG Ratio
3.23
Dividend Yield
3.40%
ROCE (Latest)
7.25%
ROE (Latest)
6.66%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Mildly Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

11What is working for the Company
OPERATING CASH FLOW(Y)

Highest at CNY 613.68 MM

INTEREST COVERAGE RATIO(Q)

The company hardly has any interest cost

DIVIDEND PAYOUT RATIO(Y)

Highest at 64.47%

NET PROFIT(9M)

Higher at CNY 287.51 MM

NET SALES(Q)

Highest at CNY 1,040.28 MM

OPERATING PROFIT(Q)

Highest at CNY 241.47 MM

OPERATING PROFIT MARGIN(Q)

Highest at 23.21 %

-2What is not working for the Company
RAW MATERIAL COST(Y)

Grown by 11.02% (YoY

CASH AND EQV(HY)

Lowest at CNY 2,383.85 MM

Here's what is working for Zhejiang Xianju Pharmaceutical Co., Ltd.

Net Profit
At CNY 287.51 MM has Grown at 64.04%
Year on Year (YoY)
MOJO Watch
Near term Net Profit trend is positive

Net Profit (CNY MM)

Operating Cash Flow
Highest at CNY 613.68 MM
in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (CNY MM)

Net Sales
Highest at CNY 1,040.28 MM
in the last five periods
MOJO Watch
Near term sales trend is positive

Net Sales (CNY MM)

Operating Profit
Highest at CNY 241.47 MM
in the last five periods
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (CNY MM)

Operating Profit Margin
Highest at 23.21 %
in the last five periods
MOJO Watch
Company's profit margin has improved

Operating Profit to Sales

Net Profit
Higher at CNY 287.51 MM
than preceding 12 month period ended Jun 2026
MOJO Watch
In the nine month period the company has already crossed sales of the previous twelve months

Net Profit (CNY MM)

Dividend Payout Ratio
Highest at 64.47%
in the last five years
MOJO Watch
Company is distributing higher proportion of profits generated as dividend

DPR (%)

Here's what is not working for Zhejiang Xianju Pharmaceutical Co., Ltd.

Cash and Eqv
Lowest at CNY 2,383.85 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is deteriorating

Cash and Cash Equivalents

Raw Material Cost
Grown by 11.02% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales

Footer loading